

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Candesartan Plus 32 mg/25 mg Tablet (DIN 02420740) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 24, 2018**.

CANDESARTAN CILEXETIL/ HYDROCHLOROTHIAZIDE

32 MG / 25 MG TABLET

00002421054	AURO-CANDESARTAN HCT	AUR	\$ 0.3008
00002420740	SANDOZ CANDESARTAN PLUS	SDZ	\$ 0.3008
00002332957	ATACAND PLUS	AZC	\$ 1.2670

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Dexiron 50 mg/ml Injection (DIN 02205963) manufactured by Luitpold Pharmaceuticals, Inc., Venofer 20 mg/ml Injection (DIN 02243716) manufactured by Luitpold Pharmaceuticals, Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Luitpold Pharmaceuticals, Inc. has advised Alberta Blue Cross that the shortage of Dexiron 50 mg/ml Injection (DIN 02205963) has been resolved.

As a result, Venofer 20 mg/ml Injection (DIN 02243716) will no longer be considered a temporary benefit for the *ADBL* after **May 24, 2018**.

Due to the shortage of Vfend 200 mg/Vial Injection (DIN 02256487) manufactured by Pfizer Canada Inc., Voriconazole 200 mg/Vial Injection (DIN 02381966) manufactured by Sandoz Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pfizer Canada Inc. has advised Alberta Blue Cross that the shortage of Vfend 200 mg/Vial Injection (DIN 02256487) has been resolved.

As a result, Voriconazole 200 mg/Vial Injection (DIN 02381966) will no longer be considered a temporary benefit for the *ADBL* after **May 31, 2018**.

... continued from previous page

Due to the shortage of Auro-Mirtazapine 15 mg Tablet (DIN 02411695) manufactured by Auro Pharma Inc., Mylan-Mirtazapine 15 mg Tablet (DIN 02256096) manufactured by Mylan Pharmaceuticals ULC, and pms-Mirtazapine 15 mg Tablet (DIN 02273942) manufactured by Pharmascience Inc., Apo-Mirtazapine 15 mg Tablet (DIN 02286610) manufactured by Apotex Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Mylan Pharmaceuticals ULC has advised Alberta Blue Cross that the shortage of Mylan-Mirtazapine 15 mg Tablet (DIN 02256096) has been resolved.

As a result, Apo-Mirtazapine 15 mg Tablet (DIN 02286610) will no longer be considered a temporary benefit for the *ADBL* after **May 31, 2018**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.736 2018/05

